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Inflammatory breast cancer (IBC) is an aggressive form of primary breast
cancer characterized by rapid onset and high risk of metastasis and poor clin-
ical outcomes. The biological basis for the aggressiveness of IBC is still not
well understood and no IBC-specific targeted therapies exist. In this study,
we report that lipocalin 2 (LCN2), a small secreted glycoprotein belonging to
the lipocalin superfamily, is expressed at significantly higher levels in IBC vs
non-IBC tumors, independently of molecular subtype. LCN2 levels were also
significantly higher in IBC cell lines and in their culture media than in non-
IBC cell lines. High expression was associated with poor-prognosis features
and shorter overall survival in IBC patients. Depletion of LCN2 in IBC cell
lines reduced colony formation, migration, and cancer stem cell populations
in vitro and inhibited tumor growth, skin invasion, and brain metastasis in
mouse models of IBC. Analysis of our proteomics data showed reduced
expression of proteins involved in cell cycle and DNA repair in LCN2-
silenced IBC cells. Our findings support that LCN2 promotes IBC tumor
aggressiveness and offer a new potential therapeutic target for IBC.
1. Introduction
Inflammatory breast cancer (IBC) is the most aggressive
and deadly variant of primary breast cancer. Although
IBC is considered rare in the United States (1–4% of all
breast cancer cases), it accounts for a disproportionate
10% of breast cancer-related deaths because of its
aggressive proliferation and metastasis and limited
Abbreviations
BrMS, brain metastasis subline; ER, estrogen receptor; ERBB2/HER2, Erb-B2 receptor tyrosine kinase 2; IBC, inflammatory breast cancer;
LCN2, Lipocalin 2; LuMS, lung metastasis subline; MAPK, mitogen-activated protein kinase; MMP-9, matrix metallopeptidase 9; MTOR,
mammalian target of rapamycin; non-IBC, non-inflammatory breast cancer; PR, progesterone receptor; RPS6KB1, ribosomal protein S6
kinase B1; shCtl, short hairpin RNA control; shLCN2, short hairpin RNA for Lipocalin 2; TNBC, triple-negative breast cancer.
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therapeutic options [1–5]. IBC disproportionately affects
young and African American women [1,6]. IBC is associ-
ated with unique clinical and biological features and a
distinctive pattern of recurrence with high incidence in
central nervous system, lung, and liver as first site of
relapse [4,7,8]. Even with multimodality treatment strate-
gies, survival rates for women with IBC are far lower
than for those with other types of breast carcinoma (non-
IBC), with estimated 5-year overall survival rates limited
to 40% vs 63% for non-IBC [4,6–9]. These features
underscore the critical need to better define the mecha-
nisms that drive the aggressive behavior of IBC and to
develop novel agents to improve the overall prognosis
for women with IBC. Efforts have been undertaken to
identify pathways and therapeutic targets distinct to IBC
and to better elucidate the mechanisms of IBC aggres-
siveness [10–15]. However, the molecular and cellular
basis for IBC aggressiveness remains unclear. Identifica-
tion of specific targets and unraveling the mechanisms of
growth and metastasis of this aggressive disease could
lead to improvements in IBC patient survival.
Lipocalin 2 [LCN2, also known as neutrophil
gelatinase-associated Lipocalin (NGAL), siderocalin,
or 24p3] is a 25-kDa secreted glycoprotein that belongs
to the lipocalin superfamily. LCN2 is known to
sequester iron, as it binds siderophore-complexed ferric
iron with high affinity, and has significant roles in
immune and inflammatory responses, angiogenesis, cell
proliferation, survival, and resistance to anticancer
therapies [16–21]. LCN2 has been implicated in the
progression of several types of human tumors, includ-
ing breast cancer, through several mechanisms, such as
stabilization of matrix metallopeptidase 9 (MMP-9),
sequestration of iron, induction of epithelial–mes-
enchymal transition, apoptosis resistance, lymphangio-
genesis, and cell cycle arrest [16–20,22–26]. Moreover,
high LCN2 expression levels have been linked with
poorer survival in patients with breast cancer [16,26–
28]. Little is known regarding the oncogenic role of
LCN2 in IBC tumors.
In the present study, we demonstrate that LCN2
was expressed at significantly higher levels in patients
with IBC and that LCN2 promoted tumor growth,
skin invasion, and metastasis in xenograft mouse mod-
els of IBC.
2. Materials and methods
2.1. Cell lines
The SUM149 cell line was purchased from Asterand
(Detroit, MI, USA), and MDA-IBC3 cell line was
generated in Dr. Woodward’s laboratory [29,30] and
cultured in Ham’s F-12 media supplemented with
10% FBS (GIBCO, Thermo Fisher, Carlsbad, CA,
USA), 1 µgmL1 hydrocortisone (#H0888, Sigma-
Aldrich, St. Louis, MO, USA), 5 µgmL1 insulin
(#12585014; Thermo Fisher), and 1% antibiotic-
antimycotic (#15240062; Thermo Fisher). HEK293T
cells were purchased from the American Type Culture
Collection (Manassas, VA, USA) and cultured in
Dulbecco’s modified Eagle’s medium supplemented
with 10% FBS and 1% penicillin and streptomycin
(#15140122; Invitrogen, Carlsbad, CA, USA). All cell
lines were kept at 37 °C in a humidified incubator
with 5% CO2 and were authenticated by short tan-
dem repeat profiling at the Cytogenetics and Cell
Authentication Core at UT MD Anderson Cancer
Center.
2.2. Lentivirus-mediated knockdown
LCN2 stable knockdown clones were generated in
SUM149 or MDA-IBC3 cells by using shRNA
(shLCN2-1: TRCN0000060289 from Sigma-Aldrich;
shLCN2-2: RHS4430-200252675 or shLCN2-3:
RHS4430-200246537 from MD Anderson’s Functional
Genomics Core Facility, Houston, TX, USA). The
MISSION(R) pLKO.1-puro Empty Vector (SHC001,
Sigma) was used as control (shCtl). HEK293T cells
were transfected with 4.05 µg of target plasmid,
pCMV-VSV-G (0.45 µg; #8584; Addgene, Watertown,
MA, USA) and pCMV delta R8.2 (3.5 µg, #12263,
Addgene) by using Lipofectamine 2000 (Life Tech-
nologies, Carlsbad, CA, USA) for 24 h. SUM149 and
MDA-IBC3 cells were incubated with the supernatant-
containing virus plus 8 µgmL1 of polybrene for
24 h. Stable cell lines were selected with 1 lgmL1 of
puromycin.
2.3. RNA isolation and real-time PCR
RNA was isolated by using TRIzol Reagent (Life Tech-
nologies) according to the manufacturer’s instructions.
The cDNA was obtained with a High Capacity cDNA
Reverse Transcription Kit with RNase Inhibitor
(Thermo Fisher Scientific). Real-time PCR was done by
using Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) on a 7500 Real-
Time PCR system (Applied Biosystems). LCN2 forward
primer: 30-CCACCTCAGACCTGATCCCA-50, reverse
primer: 30- CCCCTGGAATTGGTTGTCCTG-50;
GAPDH forward primer: 30-GAAGGTGAAGGTC
GGAGT-50, reverse primer: 30-GAAGATGGTGAT
GGGATTTC-50.
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2.4. ELISA
Human LCN2/NGAL Quantikine ELISA Kits
(#DLCN20; R&D Systems, Minneapolis, MN, USA)
were used to measure the levels of LCN2 in the cell
lines according to the manufacturer’s instructions.
Samples were assayed in duplicate.
2.5. Western blotting
Cells were lysed in RIPA buffer (Sigma) supplemented
with 10 µLmL1 phosphatase and 10 µLmL1 pro-
tease inhibitor cocktail. SDS/PAGE and immunoblot-
ting were carried out as described elsewhere [29]. The
following primary antibodies were used: LCN2 anti-
body (1 : 1000, #MAB1757SP; R&D Systems),
pMEK1/2 (1 : 1000, #9154; Cell Signaling, Danvers,
MA, USA), MEK1/2 (1 : 1000, # 8727; Cell Signal-
ing), pERK1/2 (1 : 1000, # 4370; Cell Signaling),
ERK1/2 (1 : 1000, # 9102; Cell Signaling), or GAPDH
(1 : 5000, #5174; Cell Signaling), and samples were
incubated overnight at 4 °C. Secondary antibodies
(1 : 5000), anti-rat IgG (#HAF005; R&D Systems)
and anti-rabbit IgG (#7074; Cell Signaling) were incu-
bated with the samples for 2 h at room temperature.
Immunoreactivity was visualized with ClarityTM Wes-
tern ECL Substrate (#1705061; Bio-Rad, Hercules,
CA, USA) using ImageQuant LAS4000 (GE Health-
care, Chicago, IL, USA).
2.6. Proliferation
About 2500 cells were seeded in triplicate in a 96-well
plate. Cell proliferation was measured every day for
up to 72 h with the CellTiter-Blue assay (#G8080; Pro-
mega, Madison, WI, USA) according to the manufac-
turer’s instructions. Absorbance was recorded at
OD595 nm with a Multifunctional Reader VICTOR X
3 (PerkinElmer, Waltham, MA, USA).
2.7. Colony-formation assay
About 100 SUM149 or 500 MDA-IBC3 shRNA Con-
trol or LCN2-silenced cells were plated in triplicate in
6-well plates. After 15 days, cells were fixed with
methanol for 2 min and stained with 0.2% (w/v) crys-
tal violet for 30 min. Colonies were counted using Gel-
Count (Oxford Optoronix, Abingdon, UK).
2.8. Migration and invasion assay
For the migration assay, 50 000 cells per well (triplicate)
were seeded in medium without serum onto 8 lm
polypropylene filter inserts in Boyden chambers
(Fisher). Medium with 10% FBS was added onto the
well. After 24 h, cells on the bottom of the filter were
fixed and stained with Thermo Scientific Shandon Kwik
Diff Stains (Fisher). The invasion assay was done as
described above, except that the 8 lm polypropylene fil-
ter inserts were coated with Matrigel (#CB-40234; Corn-
ing Inc., Corning, NY, USA) and incubated for 24 h.
Ten visual fields were randomly chosen under micro-
scopy and cells were quantified by using IMAGEJ software
(National Institutes of Health, Bethesda, MD, USA).
2.9. Mammosphere assay
For primary mammosphere formation, 30 000
SUM149 or MDA-IBC3 control or LCN2-knockdown
cells were plated in ULTRALOW attachment six-well
plates (Corning Inc.) in mammosphere medium
[serum-free MEM supplemented with 20 ngmL1 of
bFGF (Gibco), 20 ngmL1 epidermal growth factor
(Gibco), B27 19 (Gibco), and gentamycin/penicillin/
streptomycin (Thermo Fisher)]. After 7 days,
5 lgmL1 of MTT (Sigma-Aldrich) was added for
30 min and the mammospheres were counted using
GelCount (Oxford Optoronix). For secondary mam-
mosphere formation, primary mammospheres were dis-
sociated and counted, and 10 000 cells were plated in
the ULTRALOW attachment six-well plates in mam-
mosphere media and analyzed after 7 days.
2.10. CD44/CD24 flow cytometry
About 2.5 9 105 cells were suspended in CD24-PE
mouse anti-human (#555428; BD Biosciences) or CD24-
BV421 Mouse Anti-Human (#562789; BD Biosciences,
Franklin Lakes, NJ, USA) and CD44-FITC mouse
anti-human (#555478; BD Biosciences) or CD44-APC
Mouse anti-Human (#559942; BD Biosciences) solu-
tions and incubated for 20 min on ice. Cells only, PE/
BV421 only, and FITC/APC only were used as controls
to set the gating. Fluorescence was detected by using a
Gallios Flow Cytometer (Beckman Coulter, Brea, CA,
USA) at the Flow Cytometry and Cellular Imaging
Core Facility (UT MD Anderson Cancer Center, Hous-
ton, TX, USA). FLOWJO software (Treestar, Ashland,
OR, USA) was used to analyze the data.
2.11. Kinase enrichment analysis
The RPPA data were also used for the phosphopro-
teomic analysis using kinase enrichment analysis (KEA
—https://maayanlab.cloud/kea3/) [31]. Briefly, the 20
proteins that exhibit the highest phosphorylation fold
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change levels in control vs LCN2-silenced cells were
analyzed. Two different analyses were performed using
KEA: (a) The differentially phosphorylated proteins
are queried for enrichment of kinase substrates and (b)
the differentially phosphorylated proteins are queried
for enrichment of interacting proteins across seven
databases. The latter analysis is more general and is
not limited to only kinase substrates. Both analyses
result in the detection of kinases that are putatively
responsible for the observed phosphorylation differ-
ences. Identified proteins by both analyses were
mapped onto the STRING network (https://string-db.
org) to investigate their mutual interactions.
2.12. In vivo experiments
Four- to six-week-old female athymic SCID/Beige mice
were purchased from Harlan Laboratories (Indi-
anapolis, IN, USA) and allowed to acclimate for 1 week
before use. All mice were given free access to food and
water in a specific pathogen-free condition. All animal
experiments were done in accordance with protocols
approved by the Institutional Animal Care and Use
Committee of MD Anderson Cancer Center. Mice were
euthanized with overdose of isoflurane when they met
the institutional criteria for tumor size and overall
health condition. For primary tumor growth, cells were
injected into the orthotopic cleared mammary fat pad of
mice as previously described [32]. Briefly, 5 9 105
SUM149 shRNA Control / LCN2-knockdown cells
were injected (9 mice/Control; 10 mice/LCN2 KD).
Tumor volumes were assessed weekly by measuring pal-
pable tumors with calipers. Volume (V) was determined
as V = (L 9 W 9 W) 9 0.5, with L being length and
W width of the tumor. To determine latency, the first
day when palpable tumors appeared was used to plot
the graph. For brain metastatic colonization studies, we
followed our laboratory protocol [33]. Briefly, 1 9 106
MDA-IBC3 GFP-labeled shRNA Control/LCN2-
knockdown cells (10 mice/group) were injected via the
tail vein into SCID/Beige mice. At 12 weeks after tail-
vein injection, mice were euthanized, and brain tissue
collected and imaged with fluorescent stereomicroscopy
(SMZ1500; Nikon Instruments, Melville, NY, USA). IM-
AGEJ was used to measure GFP-positive areas to quan-
tify the area of brain tumor burden. For mice with more
than one brain metastasis, the area of each metastasis
was considered and measured.
2.13. Statistical analysis
All in vitro experiments were repeated at least three
times, and graphs depict mean  SEM. Statistical
significance was determined with Student’s t-tests (un-
paired, two-tailed) unless otherwise specified. One-way
analysis of variance was used for multiple compar-
isons. Mann–Whitney test was used when normality
was not met. LCN2 expression in breast cancer sam-
ples was analyzed in the IBC Consortium dataset [34]
for IBC and from a meta-dataset previously published
[35]. Tumor samples were stratified as LCN2-high
when expression in tumor was at least two-fold the
mean expression level measured in the normal breast
samples; otherwise, the sample was classified as LCN2-
low. Kaplan–Meier curves and log-rank tests were
used to compare survival distributions. Univariate and
multivariate Cox regression models were used to evalu-
ate the significance of LCN2 expression on overall sur-
vival. A P value of < 0.05 was considered significant.
GRAPHPAD software (GraphPad Prism 8, La Jolla, CA,
USA) was used.
3. Results
3.1. LCN2 mRNA is highly expressed in
inflammatory breast cancer
Previous studies have shown that high LCN2 expres-
sion levels were correlated with poor prognosis in
breast cancer patients [17,25–27]. We further validated
these findings by analyzing a meta-dataset of 8951
breast cancers, in which 87% of tumor samples were
classified as LCN2-low (n = 7830/8951) and 13% as
LCN2-high (n = 1121/8951). Table 1 summarizes the
clinico-pathological patient characteristics stratified by
LCN2 expression status. High expression of LCN2
was associated with variables commonly associated
with poor outcome: younger patients’ age, high grade,
advanced stage tumors (pN-positive and pT3), ductal
type, estrogen receptor (ER)-negative status, proges-
terone receptor (PR)-negative status, Erb-B2 receptor
tyrosine kinase 2 (ERBB2)-positive status, and aggres-
sive molecular subtypes [ERBB2+ and triple-negative
breast cancer (TNBC) subtypes]. In this cohort, we
also analyzed the association of LCN2 expression and
survival over time using the Kaplan–Meier method.
We found that LCN2-high tumors had significantly
shorter overall survival (P < 0.0001) than LCN2-low
tumors (Fig. 1A).
Analysis of microarray data from the IBC World
Consortium Dataset [34] consisting of IBC and non-
IBC patient samples (n = 389; IBC = 137, non-
IBC = 252) showed that LCN2 expression was signifi-
cantly higher in tumors from IBC patients compared
to non-IBC (P = 0.0003; Fig. 1B). We validated this
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finding in another independent dataset [36] that com-
pared mRNA expression of microdissected IBC and
non-IBC tumors (P = 0.0379; Fig. 1C). Here too,
LCN2 expression was higher in ER-negative IBC
patients compared to ER-positive (P = 0.0009;
Fig. 1D) and in more aggressive subtypes, ERBB2-
positive and TNBC, compared to hormone receptor
(HR)-positive/ERBB2-negative subtype (Fig. 1E).
Multivariate analysis showed that LCN2 was expressed
significantly higher in IBC tumors relative to non-IBC
tumors, independently from the molecular subtype dif-
ferences (Odds ratio, 1.71, P = 0.034; Table 2). Here
too, the survival analysis in IBC patients showed that
LCN2-high tumors had significantly shorter overall
survival (P = 0.0317) than LCN2-low tumors
(Fig. 1F). Consistent with the patient data, the levels
of LCN2 were higher in IBC cell lines (Fig. 1G) and
in the supernatants collected from IBC cell lines rela-
tive to non-IBC (Fig. 1H). Taken together, our find-
ings show that LCN2 is highly expressed in IBC
tumors and is correlated with aggressive features and
poor outcome suggesting it may contribute to the
aggressive pathobiology of IBC tumors.
3.2. LCN2-knockdown reduced aggressiveness
features in vitro
We generated stable LCN2-knockdown cell lines
[SUM149 (triple-negative IBC); MDA-IBC3 (HER2+
IBC)] to investigate the role of LCN2 in IBC aggres-
siveness in vitro and in vivo. LCN2-knockdown was
confirmed by qRT-PCR and immunoblotting (Fig. 2A,
B). Because LCN2 is a secreted protein, we evaluated
levels of LCN2 protein in the supernatants from con-
trol and LCN2-silenced IBC cell lines by using ELISA.
We observed significant reduction of secreted LCN2 in
the LCN2-silenced IBC cells (Fig. 2C). Silencing
LCN2 slightly reduced proliferation of SUM149 cells
but did not affect MDA-IBC3 cells (Fig. 2D). Deple-
tion of LCN2 reduced the capacity of the cells to form
colonies (Fig. 2E) and to migrate and invade (Fig. 3A,
B). LCN2 silencing also significantly reduced the per-
centage of cancer stem cell populations in LCN2-
silenced IBC cells relative to control, as shown by
reductions in primary and secondary mammosphere
formation efficiency (Fig. 3C,D) and CD44+CD24
cell subpopulations (Fig. 3E). These findings indicate
Table 1. Clinico-pathological characteristics of tumor samples from patients with IBC or non-IBC according to LCN2 expression. The
percentage between brackets is relative to the total number of samples informative in each column.
Characteristics Level All (n = 8951) LCN2-low (n = 7830) LCN2-high (n = 1121) P value
Age (years) ≤ 50 2587 (36%) 2218 (36%) 369 (42%) 1.10E-04
> 50 4520 (64%) 4018 (64%) 502 (58%)
Pathological grade 1 717 (11%) 680 (13%) 37 (4%) < 1.00E-06
2 2549 (41%) 2359 (43%) 190 (22%)
3 3016 (48%) 2389 (44%) 627 (73%)
Pathological node (pN) Negative 3666 (57%) 3253 (57%) 413 (53%) 3.89E-02
Positive 2788 (43%) 2426 (43%) 362 (47%)
Pathological size (pT) pT1 2116 (37%) 1912 (38%) 204 (31%) 2.00E-06
pT2 2931 (52%) 2588 (52%) 343 (53%)
pT3 604 (11%) 498 (10%) 106 (16%)
Pathological type Ductal 4027 (79%) 3492 (78%) 535 (86%) 3.00E-06
Lobular 500 (10%) 471 (11%) 29 (5%)
Other 574 (64%) 519 (12%) 55 (9%)
ER statusa Negative 2753 (31%) 1955 (25%) 798 (71%) 1.97E-215
Positive 6198 (69%) 5875 (75%) 323 (29%)
PR statusa Negative 4635 (52%) 3746 (48%) 889 (80%) 3.06E-86
Positive 4284 (48%) 4055 (52%) 229 (20%)
ERBB2 statusa Negative 7862 (88%) 6975 (89%) 887 (79%) 2.37E-21
Positive 1089 (12%) 855 (11%) 234 (21%)
HR subtypea HR+/ERBB2 5914 (66%) 5598 (72%) 316 (28%) < 1.00E-06
ERBB2+ 1089 (12%) 855 (11%) 234 (21%)
TNBC 1938 (22%) 1368 (17%) 570 (51%)






Hazard ratio (95% confidence interval)
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Fig. 1. LCN2 was highly expressed in tumors from patients with IBC. (A) High LCN2 expression was associated with shorter overall survival
in a meta-dataset of patients with non-IBC. (B, C) LCN2 mRNA expression was higher in tumors from IBC patients vs non-IBC patients in
two independent breast cancer datasets [IBC World Consortium Dataset; GSE45582]. (D) LCN2 mRNA expression was higher in ER-
negative compared to ER+ samples IBC samples. (E) LCN2 mRNA expression was higher in more aggressive molecular subtypes, ERBB2+
and TNBC, compared to HR-positive/HERBB2-negative subtype. (F) LCN2-high expression correlates with shorter overall survival in patients
with IBC. (G) LCN2 mRNA expression was higher in IBC cell lines compared to non-IBC cell lines. (H, I) LCN2 protein expression was higher
in IBC cell lines compared to non-IBC cell lines shown by (H) immunoblotting or (I) ELISA for secreted LCN2 in supernatants. Bar graphs
indicate mean  SEM from three independent experiments. GRAPHPAD PRISM software was used to obtain the P values, with Mann–Whitney
tests used to compare two categories or one-way analysis of variance to compare three or more categories. Black lines in each group (B–E,
and G) indicate mean  SD.
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that suppression of LCN2 in IBC cells reduced in vitro
aggressiveness features.
3.3. Silencing of LCN2 inhibited tumor growth
and skin invasion
To investigate the effects of LCN2 on tumor growth
and skin invasion, key characteristics of IBC tumors
[4], we injected SUM149 control or LCN2-silenced
cells into the cleared mammary fat pad of SCID/Beige
mice. Silencing of LCN2 reduced tumor volumes
(P = 0.0037; Fig. 4A) and tumor latency, that is, the
ability to initiate tumor growth: mice transplanted
with SUM149 LCN2-silenced cells took longer to initi-
ate tumors than did those transplanted with SUM149
control cells (P = 0.0145; Fig. 4B). Because IBC typi-
cally manifests with skin invasion and formation of
tumor emboli [4], we assessed skin invasion visually
during primary tumor growth, as evidenced by loss of
fur at the tumor site and skin redness and thickness,
and during tumor excision when tumors were firmly
connected with the skin. Analysis of resected tumors
showed that significantly fewer mice with SUM149
LCN2-silenced cells had skin invasion/recurrence com-
pared with mice implanted with control cells [shLCN2:
two of eight mice (25%) vs shControl: seven of eight
mice (87.5%), P = 0.01; Fig. 4C,D]. On histologic
examination, tumors generated from LCN2-silenced
cells were more differentiated than those generated
from control SUM149 cells (Fig. 4E); we further
Table 2. Univariate and multivariate Cox regression analysis of IBC patient samples vs non-IBC (n = 389).
IBC vs non-IBC
Univariate Multivariate
Odds ratio 95% CI P value Odds ratio 95% CI P value
LCN2, high vs low 2.09 1.43–3.06 1.43E-03 1.71 1.13–2.6 3.42E-02
Molecular subtype
ERBB2+ vs HR+/ERBB2 2.82 1.82–4.38 1.02E-04 2.5 1.59–3.93 8.16E-04

























































































































































































































Fig. 2. Silencing LCN2 decreased colony formation efficiency. LCN2 was knocked down (shLCN2) in two IBC cell lines (SUM149 and MDA-
IBC3) and confirmed by (A) qRT-PCR and (B) immunoblotting. (C) Secreted LCN2 measured in control and silenced cells by ELISA at the
indicated times. Bar graphs indicate mean  SEM, calculated after three independent experiments; P values from t-tests. (D) Proliferation
was evaluated in control and LCN2-silenced SUM149 and MDA-IBC3 cells with CellTiter-Blue assay on the indicated days. P values from t-
tests. (E) Cells were seeded in low numbers to measure the capacity to form colonies in LCN2 knockdown and control. Bar graphs indicate
mean  SEM, calculated after three independent experiments; P values from t-tests.
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observed tumor emboli, another hallmark of IBC
tumors, in SUM149 control-transplanted tumors but
not in tumors generated from LCN2-silenced SUM149
cells (Fig. 4E).
We recently generated xenograft mouse models of
brain and lung metastasis via tail-vein injection of IBC
cell lines [29,33]. We also showed that sublines of
SUM149 generated from brain metastases (BrMS) and
lung metastases (LuMS) have distinct morphologic
and molecular features [29]. Microarray profiling of
these sublines showed upregulation of LCN2 in the
brain metastatic sublines (Fig. S1A), and we confirmed
higher levels of secreted LCN2 in the BrMS sublines
vs LuMS by ELISA (Fig. S1B). Most recently, Chi
et al. [37] elegantly demonstrated that LCN2 promotes
brain metastatic growth in mouse models of lep-
tomeningeal metastasis, highlighting a potential brain
metastasis-promoting role for LCN2. We investigated
the functional role of LCN2 in IBC brain metastasis
by using our HER2+ MDA-IBC3 mouse model, which
has a high propensity to metastasize to the brain and
has been used to identify targets and develop therapeu-
tics against brain metastasis [29,38–40]. We found that
the brain metastatic burden was significantly lower in
mice that had received tail-vein injection of LCN2-
silenced MDA-IBC3 cells than in mice injected with
control cells (Fig. 4F, P = 0.0059). Also, fewer mice
injected with LCN2-silenced cells developed brain
metastasis [one of 10 (10%)] than did mice injected



























































































































































































































Fig. 3. LCN2 knockdown reduced aggressiveness features in vitro. (A) Migration and (B) invasion by control cells (shCtl) and LCN2-
knockdown (shLCN2) SUM149 cells. (C) Primary mammosphere formation efficiency and (D) secondary mammosphere formation efficiency.
(E) CD44+CD24 cells (marker of cancer stem cells) were measured by flow cytometry. Bar graphs indicate mean  SEM, calculated after
three independent experiments; P values from t-tests.
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trend was not statistically significant (P = 0.1409;
Fig. 4G). Representative stereofluorescence and hema-
toxylin and eosin images of brain metastasis are shown
in Fig. 4H. Overall, our findings suggest that LCN2
may drive IBC tumor progression, skin invasion/recur-
rence, and brain metastasis.
3.4. LCN2 silencing impairs cell cycle-associated
proteins
To identify potential mechanisms and pathways
involved in suppression of tumor growth and skin inva-
sion in LCN2-silenced cells, we used reverse-phase pro-
teomics assay (RPPA) profiling to compare control and
LCN2-silenced SUM149 cells. Our analysis showed
reduced expression of cell cycle-associated proteins
[such as AXL, FOXM1, Chk1, CDK1, Wee1, Aurora-
B, and cyclin-B1 and the mammalian target of rapamy-
cin (mTOR)/AKT pathway] in LCN2-silenced IBC cells
(Fig. 5A). Gene set enrichment analysis revealed several
key signaling pathways that were enriched in the control
cells, including those associated with cell cycling, DNA
repair, and mTOR signaling (Fig. 5B). Furthermore, we
performed KEA [31] on the 20 proteins that exhibited
the highest phosphorylation fold changes in LCN2-
control vs LCN2-silenced SUM149 cells (Table S1).
Based on the set of predicted activated kinases (Tables
S1 and S2), an interaction network was generated
(Fig. 5C). Based on the node degree distribution (i.e.,
the distribution of the number of interactions per gene
in the network), mitogen-activated protein kinase 1
(MAPK1; N = 10), MAPK8 (N = 7), ribosomal protein
S6 kinase B1 (RPS6KB1; N = 7), and MTOR (N = 11)
appear to be central to LCN2 action in SUM149 cells.
Our immunoblotting experiments confirmed that silenc-
ing LCN2 reduces the phosphorylated forms of MEK
(pMEK) and ERK (pERK) of the MAPK signaling
pathway (Fig. 5D). Thus, LCN2 may regulate different
pathways, including cell cycle, MAPK, and mTOR pro-
teins to promote tumor growth in IBC.
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5 P = 0.0059
SUM149 shCtl SUM149 shLCN2-1E
SUM149 shCtl SUM149 shLCN2-1
Fig. 4. Silencing LCN2 inhibited tumor growth and skin invasion. (A–C) SUM149 shRNA Ctl or LCN2-knockdown (shLCN2) cells were
transplanted orthotopically into the cleared mammary fat pad of SCID/Beige mice (n = 9/shCtl; 10/shLCN2) and tumor volume measured
weekly; (A) tumor volume, (B) tumor latency, and (C) incidence of skin invasion/recurrence after resection of primary tumors. (A, B) P values
from t-tests and (C) from Fisher’s exact test. (D, E) Hematoxylin and eosin staining of primary tumors generated from LCN2-control and
knockdown SUM149 cells. Both (D) skin invasion and (E) tumor emboli, two hallmarks of IBC, appeared only in the control-derived tumors
(arrowhead). Scale bar, 100 µm. (F) Metastatic burden (area) of each brain metastasis formed was quantified by using IMAGEJ software. BM,
brain metastasis. P values from t-tests. (G) Incidence of brain metastasis. N = 10 mice per group. Fisher’s exact test was used to obtain P
values. (H) Top, GFP imaging of brain metastasis lesions generated from tail-vein injection of GFP-labeled MDA-IBC3 shRNA Ctl or LCN2-
knockdown cells, and bottom, hematoxylin and eosin stains of brain metastasis lesions. Scale bar, 50 µm.
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4. Discussion
Inflammatory breast cancer is an aggressive form of
breast cancer with poor survival outcomes. Although
considerable effort has been undertaken to understand
the unique biology of IBC, insights are still limited as
to the molecular properties that mediate the develop-
ment and aggressiveness of IBC. Herein, we report
that the secreted glycoprotein LCN2 was highly
expressed in tumors from IBC patients and in IBC cell
lines. We further demonstrate, with in vitro and in vivo
studies, that LCN2 has a tumor promoter function in
IBC.
LCN2 has been implicated in the progression of sev-
eral types of human tumors. LCN2 expression is
higher in solid tumors than in corresponding normal
tissues [41,25], and it is mainly described as tumor pro-
moter in many cancers, including pancreas, glioblas-
toma, thyroid, kidney, esophagus, and breast cancer
[19,28,42–48].
In breast cancer, increased LCN2 expression was
associated with poor outcomes and shown to be an
independent prognostic marker of disease-specific-free
survival [27,49,48]. LCN2 also correlates with several
important unfavorable prognostic factors in breast
cancer, such as hormone-negative status, high prolifer-
ation levels, high histologic grade, and the presence of
lymph node metastases [27,49,48]. Further, serum
levels of LCN2 have been shown to correlate with can-
cer progression and higher likelihood of metastasis in
CA
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Fig. 5. Silencing of LCN2 impairs cell cycle-associated proteins. (A) The top proteins downregulated in LCN2-silenced cells compared with
control cells after RPPA proteomic analysis. (B) Gene set enrichment analysis of RPPA data identified pathways that are enriched or
downregulated in control vs LCN2-silenced SUM149 cells. (C) STRING interaction network of predicted active kinases based on enrichment
of kinase substrates and protein interactions identified using KEA. The confidence of the interaction is reflected by the edge thickness.
Based on node distribution analysis, four central proteins were identified (MAPK1, MAPK8, RPS6KB1, and MTOR). (D) Silencing of LCN2 in
SUM149 cells reduced pMEK and pERK expression.
10 Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
LCN2 promotes tumorigenesis in IBC E. S. Villodre et al.
breast cancer [26,50]. The oncogenic role of LCN2 has
been reported in xenograft and LCN2-knockout
mouse models. Disruption of the LCN2 gene in
MMTV-PyMT mice was found to suppress primary
tumor formation without affecting lung metastasis
[51]. Using the spontaneous MMTV-ErbB2(V664E)
LCN2/ mouse model, Leng et al. [18] reported
delayed tumor growth and reduced lung metastasis
burden in these LCN2/ mice. Another group showed
that injection of wild-type PyMT tumor cells into
LCN2-deficient mice did not alter primary tumor for-
mation but did significantly reduce lung metastasis
[52]. LCN2 has also been shown to promote tumor
progression in xenograft mouse models [16,26]. Consis-
tent with these studies, our current work with xeno-
graft mouse models of IBC supports that LCN2 has a
tumor promoter function in IBC tumors. We demon-
strated that silencing of LCN2 reduced tumor initia-
tion and growth, skin invasion/recurrence, and brain
metastasis burden in preclinical mouse models of IBC.
We further reported that depletion of LCN2 in IBC
cell cultures reduced features associated with aggres-
siveness in vitro, including migration, invasion, and
cancer stem cell populations. Others have also found
that reduction of LCN2 levels affected the same fea-
tures in MDA-MB-231 cells (TNBC cell line) and in
SK-BR-3 (HER2+ breast cancer cell line) [18,26]. How-
ever, our data demonstrating higher levels of secreted
LCN2 in IBC vs non-IBC cell lines and showing sig-
nificant inhibition of key IBC tumor features such as
tumor emboli/skin invasion in LCN2-silenced tumors
suggest that LCN2 may exert its influence via an IBC-
specific mechanism. The LCN2 protein has many func-
tions, including transport of fatty acids and iron,
induction of apoptosis, suppression of bacterial
growth, and modulation of inflammatory responses
[16–20,26,53]. In malignant cells, LCN2 promotes
oncogenesis through several mechanisms, including
stabilization of MMP-9, sequestration of iron, induc-
tion of EMT, apoptosis resistance, and regulation of
cell cycling [16–20,26,53]. Here, we report that LCN2
could regulate cell cycle-associated proteins such as
FOXM1, Chk1, CDK1, Aurora-B, Wee1, and cyclin-
B1 to promote its oncogenic role in IBC tumors.
Others have also found that silencing of LCN2
affected the expression of cell cycle proteins by reduc-
ing cyclin-D1 and inducing p21, resulting in G0-G1
cell cycle arrest [22,24,25].
LCN2 is also a potential therapeutic target in cancer
and other diseases. An antibody against LCN2 was
found to decreased lung metastasis in a 4T1-induced
aggressive mammary tumor model [18]. In cervical
cancer cells, treatment with LCN2-neutralizing
antibody reduced the migration and invasion of cells
that overexpressed LCN2 [54]. In other diseases, use of
an anti-LCN2-neutralizing antibody showed reductions
in reperfusion injury after stroke and attenuated skin
lesions in a psoriasis mouse model [55,56]. These find-
ings suggest that LCN2 could be an exploitable thera-
peutic target in IBC and other aggressive tumors.
Further studies are needed to explore therapeutic
strategies in IBC models by using antibodies against
LCN2 or targeting LCN2-associated molecular path-
ways, including those involved in cell cycling.
5. Conclusion
In summary, our studies provide evidence, for the first
time, that LCN2 is highly upregulated in IBC tumors
and that it is required for tumor growth and skin inva-
sion in mouse models of IBC; our findings further sug-
gest that LCN2 could be a therapeutic target for IBC
and other aggressive cancers.
Acknowledgements
We thank Christine F. Wogan, MS, ELS, of MD
Anderson’s Division of Radiation Oncology for scien-
tific editing and review of the manuscript. The Func-
tional Genomics Core Facility at UT MD Anderson
Cancer Center and the Flow Cytometry and Cellular
Imaging Core Facility are both funded through NCI
grant P30 CA016672 to the University of Texas MD
Anderson Cancer Center. This study was supported in
part by the following grants: UPR/MDACC Partner-
ship for Excellence in Cancer Research
(U54CA096297-CA096300 to BGD), Susan G. Komen
Career Catalyst Research Grant (CCR16377813 to
BGD), American Cancer Society Research Scholar
grant (RSG-19–126–01 to BGD), and State of Texas
Morgan Welch Welch Inflammatory Breast Cancer
Program.
Data accessibility
The data that support the findings of this study are
available from the corresponding author (bgde-
beb@mdanderson.org) upon reasonable request. Addi-
tional data are available as supplementary material.
Author contributions
ESV and BGD conceived and designed the project,
performed most of the experiments, analyzed the data,
and interpreted the results. XH, RL, WB, SRS, and
KG performed some experiments. PF, FB, and XS
11Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
E. S. Villodre et al. LCN2 promotes tumorigenesis in IBC
helped with data analysis. JS provided statistical analy-
sis support. SK provided pathological expertise and
analysis of xenograft tumors. SVL, FB, GS-S, PV-M,
NTU, WAW, and DT provided resources and con-
tributed to revision of the manuscript. ESV and BGD
wrote and edited the manuscript with input from all
other authors.
Conflict of interest
The authors declare no conflict of interest.
References
1 Chang S, Parker SL, Pham T, Buzdar AU & Hursting
SD (1998) Inflammatory breast carcinoma incidence
and survival: the surveillance, epidemiology, and end
results program of the National Cancer Institute, 1975–
1992. Cancer 82, 2366–2372.
2 Dirix LY, Van Dam P, Prove A & Vermeulen PB
(2006) Inflammatory breast cancer: current
understanding. Curr Opin Oncol 18, 563–571.
3 Hance KW, Anderson WF, Devesa SS, Young HA &
Levine PH (2005) Trends in inflammatory breast
carcinoma incidence and survival: the surveillance,
epidemiology, and end results program at the National
Cancer Institute. J Natl Cancer Inst 97, 966–975.
4 Robertson FM, Bondy M, Yang W, Yamauchi H,
Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross
H, Bidaut L, Player AN et al. (2010) Inflammatory
breast cancer: the disease, the biology, the treatment.
CA Cancer J Clin 60, 351–375.
5 Wang Z, Chen M, Pan J, Wang X, Chen XS & Shen
KW (2020) Pattern of distant metastases in
inflammatory breast cancer - a large-cohort
retrospective study. J Cancer 11, 292–300.
6 Abraham HG, Xia Y, Mukherjee B & Merajver SD
(2021) Incidence and survival of inflammatory breast
cancer between 1973 and 2015 in the SEER database.
Breast Cancer Res Treat 185, 229–238.
7 Cristofanilli M, Valero V, Buzdar AU, Kau SW,
Broglio KR, Gonzalez-Angulo AM, Sneige N, Islam R,
Ueno NT, Buchholz TA et al. (2007) Inflammatory
breast cancer (IBC) and patterns of recurrence:
understanding the biology of a unique disease. Cancer
110, 1436–1444.
8 Fouad TM,KogawaT, LiuDD, ShenY,MasudaH, El-
ZeinR,WoodwardWA,Chavez-MacGregorM,Alvarez
RH,Arun B et al. (2015) Overall survival differences
between patients with inflammatory and noninflammatory
breast cancer presenting with distantmetastasis at
diagnosis.Breast Cancer Res Treat 152, 407–416.
9 Dawood S, Ueno NT, Valero V, Woodward WA,
Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM
& Cristofanilli M (2011) Differences in survival among
women with stage III inflammatory and
noninflammatory locally advanced breast cancer appear
early: a large population-based study. Cancer 117,
1819–1826, doi: 10.1002/cncr.25682
10 Costa R, Santa-Maria CA, Rossi G, Carneiro BA,
Chae YK, Gradishar WJ, Giles FJ & Cristofanilli M
(2017) Developmental therapeutics for inflammatory
breast cancer: biology and translational directions.
Oncotarget 8, 12417–12432.
11 Kleer CG, van Golen KL, Braun T & Merajver SD
(2001) Persistent E-cadherin expression in inflammatory
breast cancer. Mod Pathol 14, 458–464.
12 van Golen KL, Wu ZF, Qiao XT, Bao LW & Merajver
SD (2000) RhoC GTPase, a novel transforming
oncogene for human mammary epithelial cells that
partially recapitulates the inflammatory breast cancer
phenotype. Cancer Res 60, 5832–5838.
13 Villodre ES, Gong Y, HuX, Huo L, Yoon EC, UenoNT,
WoodwardWA, Tripathy D, Song J &Debeb BG (2020)
NDRG1 expression is an independent prognostic factor in
inflammatory breast cancer.Cancers (Basel) 12, 3711.
14 Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T,
Lim B & Ueno NT (2020) Targeting signaling pathways
in inflammatory breast cancer. Cancers 12, 2479.
15 Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ,
Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC,
Hortobagyi GN et al. (2009) Epidermal growth factor
receptor tyrosine kinase inhibitor reverses mesenchymal
to epithelial phenotype and inhibits metastasis in
inflammatory breast cancer. Clin Cancer Res 15, 6639–
6648.
16 Fernandez CA, Yan L, Louis G, Yang J, Kutok JL &
Moses MA (2005) The matrix metalloproteinase-9/
neutrophil gelatinase-associated lipocalin complex plays
a role in breast tumor growth and is present in the
urine of breast cancer patients. Clin Cancer Res 11,
5390–5395.
17 Iannetti A, Pacifico F, Acquaviva R, Lavorgna A,
Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni
A, Vuttariello E et al. (2008) The neutrophil gelatinase-
associated lipocalin (NGAL), a NF-kappaB-regulated
gene, is a survival factor for thyroid neoplastic cells.
Proc Natl Acad Sci USA 105, 14058–14063.
18 Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B,
Zhang W, Pusztai L, Symmans WF et al. (2009)
Inhibition of lipocalin 2 impairs breast tumorigenesis
and metastasis. Cancer Res 69, 8579–8584.
19 Leung L, Radulovich N, Zhu CQ, Organ S, Bandarchi
B, Pintilie M, To C, Panchal D & Tsao MS (2012)
Lipocalin2 promotes invasion, tumorigenicity and
gemcitabine resistance in pancreatic ductal
adenocarcinoma. PLoS One 7, e46677.
20 Shiiba M, Saito K, Fushimi K, Ishigami T, Shinozuka
K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A,
12 Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
LCN2 promotes tumorigenesis in IBC E. S. Villodre et al.
Sakamoto Y et al. (2013) Lipocalin-2 is associated with
radioresistance in oral cancer and lung cancer cells. Int
J Oncol 42, 1197–1204.
21 Yang J & Moses MA (2009) Lipocalin 2: a multifaceted
modulator of human cancer. Cell Cycle 8, 2347–2352,
doi: 10.4161/cc.8.15.9224
22 Chiang KC, Yeh TS, Wu RC, Pang JS, Cheng CT, Wang
SY, Juang HH & Yeh CN (2016) Lipocalin 2 (LCN2) is a
promising target for cholangiocarcinoma treatment and
bile LCN2 level is a potential cholangiocarcinoma
diagnostic marker. Sci Rep 6, 36138.
23 Jung M, Oren B, Mora J, Mertens C, Dziumbla S,
Popp R, Weigert A, Grossmann N, Fleming I & Brune
B (2016) Lipocalin 2 from macrophages stimulated by
tumor cell-derived sphingosine 1-phosphate promotes
lymphangiogenesis and tumor metastasis. Sci Signal 9,
ra64, doi: 10.1126/scisignal.aaf3241
24 Tung MC, Hsieh SC, Yang SF, Cheng CW, Tsai RT,
Wang SC, Huang MH & Hsieh YH (2013) Knockdown
of lipocalin-2 suppresses the growth and invasion of
prostate cancer cells. Prostate 73, 1281–1290, doi: 10.
1002/pros.22670
25 Xu J, Lv S, Meng W & Zuo F (2020) LCN2 mediated
by IL-17 affects the proliferation, migration, invasion
and cell cycle of gastric cancer cells by targeting SLPI.
Cancer Manag Res 12, 12841–12849.
26 Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton
MC, Kung AL, Strong RK, Zurakowski D & Moses
MA (2009) Lipocalin 2 promotes breast cancer
progression. Proc Natl Acad Sci USA 106, 3913–3918.
27 Bauer M, Eickhoff JC, Gould MN, Mundhenke C,
Maass N & Friedl A (2008) Neutrophil gelatinase-
associated lipocalin (NGAL) is a predictor of poor
prognosis in human primary breast cancer. Breast
Cancer Res Treat 108, 389–397.
28 Candido S, Abrams SL, Steelman LS, Lertpiriyapong
K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G,
Cervello M, Polesel J et al. (2016) Roles of NGAL and
MMP-9 in the tumor microenvironment and sensitivity
to targeted therapy. Biochim Biophys Acta 1863, 438–
448.
29 Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu
K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe
AR et al. (2016) miR-141-mediated regulation of brain
metastasis from breast cancer. J Natl Cancer Inst 108,
djw026.
30 Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T,
Li L, Spaeth E, Xu W, Zhang X, Lewis MT et al.
(2010) Mesenchymal stem cells promote mammosphere
formation and decrease E-cadherin in normal and
malignant breast cells. PLoS One 5, e12180.
31 Lachmann A & Ma’ayan A (2009) KEA: kinase
enrichment analysis. Bioinformatics 25, 684–686.
32 Debeb BG, Lacerda L, Xu W, Larson R, Solley T,
Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S,
Reuben JM et al. (2012) Histone deacetylase inhibitors
stimulate dedifferentiation of human breast cancer cells
through WNT/beta-catenin signaling. Stem Cells 30,
2366–2377, doi: 10.1002/stem.1219
33 Hu X, Villodre ES, Woodward WA & Debeb BG (2021)
Modeling brain metastasis via tail-vein injection of
inflammatory breast cancer cells. J Vis Exp. 168, e62249.
34 Van Laere SJ, UenoNT, Finetti P, Vermeulen P, Lucci A,
Robertson FM,MarsanM, Iwamoto T, Krishnamurthy
S,MasudaH et al. (2013) Uncovering the molecular
secrets of inflammatory breast cancer biology: an
integrated analysis of three distinct affymetrix gene
expression datasets.Clin Cancer Res 19, 4685–4696.
35 Bertucci F, Finetti P, Goncalves A & Birnbaum D
(2020) The therapeutic response of ER+/HER2- breast
cancers differs according to the molecular Basal or
Luminal subtype. NPJ Breast Cancer 6, 8.
36 Woodward WA, Krishnamurthy S, Yamauchi H, El-
Zein R, Ogura D, Kitadai E, Niwa S, Cristofanilli M,
Vermeulen P, Dirix L et al. (2013) Genomic and
expression analysis of microdissected inflammatory
breast cancer. Breast Cancer Res Treat 138, 761–772.
37 Chi Y, Remsik J, Kiseliovas V, Derderian C, Sener U,
Alghader M, Saadeh F, Nikishina K, Bale T,
Iacobuzio-Donahue C et al. (2020) Cancer cells deploy
lipocalin-2 to collect limiting iron in leptomeningeal
metastasis. Science 369, 276–282.
38 Fukumura K, Malgulwar PB, Fischer GM, Hu X, Mao
X, Song X, Hernandez SD, Zhang XH, Zhang J, Parra
ER et al. (2021) Multi-omic molecular profiling reveals
potentially targetable abnormalities shared across
multiple histologies of brain metastasis. Acta
Neuropathol 141, 303–321.
39 Smith DL, Debeb BG, Thames HD & Woodward WA
(2016) Computational modeling of micrometastatic
breast cancer radiation dose response. Int J Radiat
Oncol Biol Phys 96, 179–187.
40 Villodre ES, Hu X, Larson R, Eckhardt BL, Gong Y,
Huo L, Song J, Krishnamurthy S, Ibrahim NK, Ueno
NT et al. (2020) Ndrg1-egfr axis in inflammatory breast
cancer tumorigenesis and brain metastasis [abstract]. In:
Proceedings of the 2019 San Antonio Breast Cancer
Symposium; 2019 Dec 10-14; San Antonio, TX, Vol.
80. AACR Cancer Res, Philadelphia, PA.
41 Candido S, Maestro R, Polesel J, Catania A, Maira F,
Signorelli SS, McCubrey JA & Libra M (2014) Roles of
neutrophil gelatinase-associated lipocalin (NGAL) in
human cancer. Oncotarget 5, 1576–1594.
42 Du Z, Wu B, Xia Q, Zhao Y, Lin L, Cai Z, Wang S,
Li E, Xu L, Li Y et al. (2019) LCN2-interacting
proteins and their expression patterns in brain tumors.
Brain Res 1720, 146304.
43 Du ZP, Wu BL, Xie YM, Zhang YL, Liao LD, Zhou
F, Xie JJ, Zeng FM, Xu XE, Fang WK et al. (2015)
Lipocalin 2 promotes the migration and invasion of
13Molecular Oncology (2021) ª 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies
E. S. Villodre et al. LCN2 promotes tumorigenesis in IBC
esophageal squamous cell carcinoma cells through a
novel positive feedback loop. Biochim Biophys Acta
1853, 2240–2250.
44 Gomez-Chou SB, Swidnicka-Siergiejko AK, Badi N,
Chavez-Tomar M, Lesinski GB, Bekaii-Saab T, Farren
MR, Mace TA, Schmidt C, Liu Y et al. (2017)
Lipocalin-2 promotes pancreatic ductal adenocarcinoma
by regulating inflammation in the tumor
microenvironment. Cancer Res 77, 2647–2660.
45 Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K,
Miyasaka Y, Ohtsuka T, Saito D, Nakamura M,
Ohkawa Y et al. (2019) CLEC3A, MMP7, and LCN2
as novel markers for predicting recurrence in resected
G1 and G2 pancreatic neuroendocrine tumors. Cancer
Med 8, 3748–3760.
46 Santiago-Sanchez GS, Pita-Grisanti V, Quinones-Diaz
B, Gumpper K, Cruz-Monserrate Z & Vivas-Mejia PE
(2020) Biological functions and therapeutic potential of
lipocalin 2 in cancer. Int J Mol Sci 21, 4365.
47 Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C,
Mori K, Pillebout E, Berger T, Mak TW, Knebelmann
B et al. (2010) Lipocalin 2 is essential for chronic
kidney disease progression in mice and humans. J Clin
Invest 120, 4065–4076.
48 Wenners AS, Mehta K, Loibl S, Park H, Mueller B,
Arnold N, Hamann S, Weimer J, Ataseven B, Darb-
Esfahani S et al. (2012) Neutrophil gelatinase-associated
lipocalin (NGAL) predicts response to neoadjuvant
chemotherapy and clinical outcome in primary human
breast cancer. PLoS One 7, e45826.
49 Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark
GM & Gould MN (1998) Heterogeneous expression of
the lipocalin NGAL in primary breast cancers. Int J
Cancer 79, 565–572.
50 Provatopoulou X, Gounaris A, Kalogera E, Zagouri F,
Flessas I, Goussetis E, Nonni A, Papassotiriou I &
Zografos G (2009) Circulating levels of matrix
metalloproteinase-9 (MMP-9), neutrophil gelatinase-
associated lipocalin (NGAL) and their complex MMP-
9/NGAL in breast cancer disease. BMC Cancer 9, 390.
51 Berger T, Cheung CC, Elia AJ & Mak TW (2010)
Disruption of the Lcn2 gene in mice suppresses primary
mammary tumor formation but does not decrease lung
metastasis. Proc Natl Acad Sci USA 107, 2995–3000.
52 Oren B, Urosevic J, Mertens C, Mora J, Guiu M,
Gomis RR, Weigert A, Schmid T, Grein S, Brune B
et al. (2016) Tumour stroma-derived lipocalin-2
promotes breast cancer metastasis. J Pathol 239, 274–
285.
53 Hu C, Yang K, Li M, Huang W, Zhang F & Wang H
(2018) Lipocalin 2: a potential therapeutic target for
breast cancer metastasis. Onco Targets Ther 11, 8099–
8106.
54 Chung IH, Wu TI, Liao CJ, Hu JY, Lin YH, Tai PJ,
Lai CH & Lin KH (2016) Overexpression of lipocalin 2
in human cervical cancer enhances tumor invasion.
Oncotarget 7, 11113–11126.
55 Shao S, Cao T, Jin L, Li B, Fang H, Zhang J, Zhang
Y, Hu J & Wang G (2016) Increased lipocalin-2
contributes to the pathogenesis of psoriasis by
modulating neutrophil chemotaxis and cytokine
secretion. J Invest Dermatol 136, 1418–1428.
56 Wang G, Weng YC, Chiang IC, Huang YT, Liao YC,
Chen YC, Kao CY, Liu YL, Lee TH & Chou WH
(2020) Neutralization of lipocalin-2 diminishes stroke-
reperfusion injury. Int J Mol Sci 21, 6253.
Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Fig. S1. LCN2 expression is higher in sublines gener-
ated from brain metastasis (BrMS) than those gener-
ated from lung metastasis (LuMS). (A) Microarray
analysis of sublines generated from BrMS or LuMS of
SUM149 cells showed LCN2 to be one of the top
upregulated genes in BrMS (red arrow). Samples are
described in Debeb 2016 [29]. (B) LCN2 is secreted in
higher levels in BrMS vs LuMS.
Table S1. Top kinases predicted to be activated based
on kinase-substrate interactions of differentially phos-
phorylated proteins.
Table S2. Top kinases predicted to be activated based
on kinase-substrate and protein-protein interaction
analysis of differentially phosphorylated proteins
across 10 different knowledge bases.
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